New drug combo tested to boost pancreatic cancer surgery success
NCT ID NCT06177522
Summary
This study is testing whether combining an immunotherapy drug (adebrelimab) with standard chemotherapy before surgery is safe and effective for people with operable pancreatic cancer. The goal is to shrink the tumor first to make surgery more successful and reduce the chance of the cancer coming back. About 30 participants will receive the drug combination for two cycles, followed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wang Sizhen
Nanjing, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.